Acelyrin has in-licensed izokibep, an antibody drug developed by Affibody that could offer advantages compared to currently available monoclonal antibodies. The drug addresses the same target as blockbuster immunology drugs marketed by Novartis and Eli Lilly.
The FDA’s review of a post-marketing study for Pfizer blockbuster anti-inflammatory drug Xeljanz found a higher risk of cardiovascular problems and cancer, and the agency is requiring additional warnings flagging those risks. The updated warnings extend to AbbVie and Eli Lilly medicines in the same drug class.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The $495 million innovation collaboration between GlaxoSmithKline and early-stage investor Avalon Ventures has produced its first fruits in the form of a company initially focused on treating celiac disease. Sitari Pharmaceuticals launched today with a $10 million Series A from Avalon and GSK and technology from Stanford University. It’s still in the early discovery phase, […]
For people with autoimmune disease, the temperature, humidity or barometric pressure on any given day could mean more pain, or less pain, than the day before. Giving those people tools to prepare for what their symptoms might be has so far been a winning idea for mobile health company Predictably Well. While AccuWeather and Weather.com […]
MADRID (IMNG) – Researchers have begun testing whether immunologic modification can forestall rheumatoid arthritis in people at high risk for the disease and also have identified smoking and overweight as two modifiable risk factors strongly linked to disease onset. In a group of 55 people without rheumatoid arthritis (RA) who were enrolled because of a […]
Another early stage California company in stealth mode has garnered a round of financing. This time it’s a biotech company called Nurix Inc., founded by three University of California, San Francisco and University of California, Berkeley researchers to leverage their drug discovery platform and develop new therapeutics for inflammatory diseases. Nurix revealed the closing of […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A biopharmaceutical company that’s already raised at least $42 million for its celiac disease drug now has $6 million more as it works through a second phase 2 trial. Alvine Pharmaceuticals’ lead candidate is a mix of two recombinant gluten-specific proteases that’s designed to be used along with a gluten-free diet to prevent immune reactions […]
The approval of Human Genome Sciences/GlaxoSmithKline’s Benlysta last year ended a drought of new drug approvals for the autoimmune disease lupus that had lasted more than half a century. A lengthy pipeline of drugs is hoping to follow suit, including a preclinical biologic compound from a University of Washington spinoff that is hoping to progress […]
Gliknik, which is testing cancer drugs and has developed a compound that it hopes will mimic the effects of IVIG, has just raised $4.9 million, some of it coming from Baxter Ventures.